Fenfluramine treatment for Dravet syndrome: Long term real‐world analysis demonstrates safety and reduced health care burden

作者：Alessandra Boncristiano, S. Balestrini, Viola Doccini, N. Specchio, N. Pietrafusa, M. Trivisano, F. Darra, A. Cossu, D. Battaglia, Michela Quintiliani, M. Luigia Gambardella, E. Parente, Rita Monni, S. Matricardi, Carla Marini, F. Ragona, Tiziana Granata, P. Striano, A. Riva, R. Guerrini · 发表于：Epilepsia · 年份：2024 · DOI：10.1111/epi.18241 · 被引用次数：19 · 研究领域：Medicine

Fenfluramine (FFA), stiripentol (STP), and cannabidiol (CBD) are approved add‐on therapies for seizures in Dravet syndrome (DS). We report on the long‐term safety and health care resource utilization (HCRU) of patients with DS treated with FFA under an expanded access program (EAP).